120 related articles for article (PubMed ID: 15883249)
1. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
[No Abstract] [Full Text] [Related]
2. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
3. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
Au WY; Li CK; Lee V; Yuen HL; Yau J; Chan GC; Ha SY; Kwong YL
Pediatr Blood Cancer; 2012 Apr; 58(4):630-2. PubMed ID: 21898784
[TBL] [Abstract][Full Text] [Related]
4. Oral arsenic treatment of leukemia and the risk of porphyria.
Au WY; Tam S; Fong BM; Kwong YL
Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
[No Abstract] [Full Text] [Related]
5. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
6. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Yoon HS; Park TS; Jeong KH
Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
[No Abstract] [Full Text] [Related]
7. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
8. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
9. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
10. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
11. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
[No Abstract] [Full Text] [Related]
12. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
Tedeschi A; Cairoli R; Marenco P; Nosari A; Tresoldi E; Di Bona E; Montillo M; Morra E
Leukemia; 2002 Dec; 16(12):2455-6. PubMed ID: 12454753
[No Abstract] [Full Text] [Related]
13. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
Falchi L; Verstovsek S; Ravandi-Kashani F; Kantarjian HM
Cancer; 2016 Apr; 122(8):1160-8. PubMed ID: 26716387
[TBL] [Abstract][Full Text] [Related]
14. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
Fukuda M
Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808
[TBL] [Abstract][Full Text] [Related]
15. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
[TBL] [Abstract][Full Text] [Related]
17. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
[No Abstract] [Full Text] [Related]
18. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide associated toothache.
Siderov J; Duggan J
J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
[TBL] [Abstract][Full Text] [Related]
20. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
[No Abstract] [Full Text] [Related]
[Next] [New Search]